Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ISA 2020 | Amyloidosis classification and epidemiology

Joan Bladé • 4 Sep 2020
ISA 2020
Amyloidosis Rare Diseases

Joan Blade, MD, PhD, Hospital Clínic de Barcelona, Barcelona, Spain, discusses amyloidosis classification and epidemiology. Specifically highlighted is AL amyloidosis, systemic amyloidosis, ATTR amyloidosis and other forms of secondary amyloidosis related to inflammatory processes. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Joan Bladé

Looking forward to ISA 2022
2:36
Looking forward to ISA 2022
Joan Bladé • 12 May 2022
How the amyloidosis treatment landscape has transformed in recent years
1:02
How the amyloidosis treatment landscape has transformed in recent years
Joan Bladé • 12 May 2022
Managing and treating renal impairment in multiple myeloma
3:26
Managing and treating renal impairment in multiple myeloma
Joan Bladé • 12 May 2022
ISA 2020: continuing the amyloidosis conversation
10:09
ISA 2020: continuing the amyloidosis conversation
Joan Bladé • 2 Sep 2020

Related Videos

Self-administration of bortezomib in myeloma and amyloidosis: feasibility study findings
3:29
Self-administration of bortezomib in myeloma and amyloidosis: feasibility study findings
Aditya Nair • 25 Sep 2026
BPDCN: unmet needs, CD123-targeted therapies and novel targets
15:50
BPDCN: unmet needs, CD123-targeted therapies and novel targets
Naveen Pemmaraju • 19 Sep 2026
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
1:39
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
Elena Zamagni • 25 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals